The global next generation sequencing market was valued at USD 23.3 Billion in 2024, with projections to reach USD 85.4 Billion by 2033. The market is expected to grow at a CAGR of 15.5% during the forecast period from 2025 to 2033. Growth is driven by technological advancements, increasing clinical applications, demand for bioinformatics tools, and a rising focus on precision medicine. The market is currently dominated by North America with a 39.7% share.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
Next Generation Sequencing Market Key Takeaways
- Current Market Size: USD 23.3 Billion (2024)
- CAGR: 15.5% (2025-2033)
- Forecast Period: 2025-2033
- North America dominates with a market share of over 39.7% in 2024.
- The market growth is fueled by advancements in genomic technology and the increasing demand for personalized medicine.
- Targeted resequencing leads the sequencing type segment with around 57.6% share in 2024.
- Reagents and consumables represent the largest product type segment, holding approximately 59.7% share in 2024.
- Sequencing by synthesis technology accounts for around 75.7% of the market share in 2024.
- Biomarker and cancer is the leading application segment with about 31.9% market share in 2024.
- Academic institutes and research centers lead the end-user segment with approximately 58.3% market share in 2024.
Request for a Free Sample Report: https://www.imarcgroup.com/next-generation-sequencing-market/requestsample
Market Growth Factors
The market for next generation sequencing is expected to grow at a steady pace due to continuous advancements in genomic technology and growing demand for personalized medicine. It is used for diagnosis, drug discovery and precision agriculture supported by the advent of high-throughput and cost-effective sequencing. The increasing use of genomics and national government support for research programs continues to catalyze the uptake of NGS in both research and clinical applications. Increased accuracy and efficiency of NGS is being supported by advancements in long-read sequencing and bioinformatics tools, enabling wider application of NGS to noninvasive prenatal testing and cancer diagnostics.
Market growth in the country is mainly due to large government funding for precision medicine, a well-established healthcare system, and increasing demand for genomic technologies for research and clinical applications. The use of NGS to diagnose and treat cancers, particularly via tumor profiling and liquid biopsy, is likely to aid market expansion due to its ability to improve patient outcomes. Easing this market's growth, in addition to the increase in regulatory policies for the adoption of NGS diagnostic solutions, are studies of ctDNA, like the one done by NeoGenomics.
The market for sequencing instruments, sequencing-related chemistry products, and analysis and interpretation platforms is expanding, with the genomics market being worth USD 33.9 Billion in 2023. The increased throughput and decreased cost per base from new sequencing platforms, and longer and more accurate reads from advances in sequencing chemistry, artificial intelligence, and cloud computing from companies like Ultima Genomics and Nvidia, continue to drive DNA sequencing forward. The increased demand for bioinformatics tools and data analysis to harness NGS data increases the value of the data produced. In 2023, the global bioinformatics market had a value of USD 12.3 Billion.
Market Segmentation
Sequencing Type:
- Whole Genome Sequencing
- Targeted Resequencing: Represents about 57.6% market share in 2024. It focuses on sequencing specific genomic regions, providing deeper sequencing depth and cost efficiency, widely used in clinical diagnostics and research.
- Whole Exome Sequencing
- RNA Sequencing
- CHIP Sequencing
- De Novo Sequencing
- Methyl Sequencing
- Others
Product Type:
- Instruments
- Reagents and Consumables: Holds approximately 59.7% market share in 2024, crucial for all sequencing workflow stages including sample preparation, library construction, and quality control.
- Software and Services
Technology:
- Sequencing by Synthesis: With around 75.7% market share in 2024, this technology is favored for its accuracy, scalability, and broad application across genomics and clinical diagnostics.
- Ion Semiconductor Sequencing
- Single-Molecule Real-Time Sequencing
- Nanopore Sequencing
- Others
Application:
- Biomarker and Cancer: Leading application with 31.9% market share in 2024, leveraging NGS for early cancer detection, personalized treatments, and comprehensive genomic profiling.
- Drug Discovery and Personalized Medicine
- Genetic Screening
- Diagnostics
- Agriculture and Animal Research
- Others
End-User:
- Academic Institutes & Research Centers: Around 58.3% market share in 2024, driven by government and private funding supporting genomic research.
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Others
Regional Insights
The next generation sequencing market in North America accounted for more than 39.7% market share in 2024 because a well-established healthcare research infrastructure exists, clinical laboratories commonly use NGS, and a strong healthcare system has academic institutions, research hospitals, and biotech companies. A large network of genetic testing laboratories in North America has eased the adoption of NGS for diagnostic tests, prenatal testing, pharmacogenomics and infectious diseases.
Recent Developments & News
- March 2024: MedGenome partnered with the Darshan GIVA Foundation to advance TB diagnosis and treatment using whole genome sequencing.
- March 2024: seqWell launched the ExpressPlex HT Library Preparation Kit, enabling multiplexing of up to 6,144 samples in a 384-well format.
- March 2023: SOPHiA GENETICS partnered with Qiagen to integrate QIAseq reagent technology with its DDM platform to improve tumor analysis.
- January 2023: QIAGEN formed a strategic partnership with Helix to advance NGS companion diagnostics for hereditary diseases.
- April 2022: Thermo Fisher Scientific introduced the Ion Torrent Genexus Dx Integrated Sequencer, an automated platform delivering results within one day.
Key Players
- 10x Genomics Inc.
- Agilent Technologies, Inc.
- BGI Genomics (BGI Group)
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific SE
- F. Hoffmann-La Roche Ltd. (Roche Holding AG)
- Illumina, Inc.
- Macrogen Inc.
- Novogene Co., Ltd.
- QIAGEN N.V.
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
